메뉴 건너뛰기




Volumn 13, Issue 16, 2012, Pages 1937-1950

Development of a pharmacogenetic-guided warfarin dosing algorithm for Puerto Rican patients

Author keywords

algorithm; CYP2C9; genotyping; personalized medicine; pharmacogenetics; VKORC1; warfarin

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

EID: 84870838007     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.171     Document Type: Article
Times cited : (26)

References (46)
  • 1
    • 47949086046 scopus 로고    scopus 로고
    • Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
    • Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
    • (2008) Clin. Pharmacol. Ther , vol.84 , Issue.3 , pp. 326-331
    • Gage, B.F.1    Eby, C.2    Johnson, J.A.3
  • 2
    • 60849097257 scopus 로고    scopus 로고
    • Estimation of warfarin dose with clinical and pharmacogenetic data
    • Klein TE, Altman RB, Eriksson N. Estimation of warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
    • (2009) N. Engl. J. Med , vol.360 , pp. 753-764
    • Klein, T.E.1    Altman, R.B.2    Eriksson, N.3
  • 3
    • 42449136621 scopus 로고    scopus 로고
    • Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multiethnic population: Comparison with other equations
    • Wu AH, Wang P, Smith A. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multiethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008).
    • (2008) Pharmacogenomics , vol.9 , Issue.2 , pp. 169-178
    • Wu, A.H.1    Wang, P.2    Smith, A.3
  • 4
    • 56549125038 scopus 로고    scopus 로고
    • Pharmacogenetics of warfarin: Development of a dosing algorithm for Brazilian patients
    • Perini JA, Struchiner CJ, Silva-Assunção E. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728 (2008).
    • (2008) Clin. Pharmacol. Ther , vol.84 , pp. 722-728
    • Perini, J.A.1    Struchiner, C.J.2    Silva-Assunção, E.3
  • 5
    • 23044440450 scopus 로고    scopus 로고
    • The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
    • Sconce EA, Khan TI, Wynne HA. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
    • (2005) Blood , vol.106 , pp. 2329-2333
    • Sconce, E.A.1    Khan, T.I.2    Wynne, H.A.3
  • 7
    • 84857011893 scopus 로고    scopus 로고
    • Prediction of warfarin dose reductions in Puerto Rican patients based on combinatorial CYP2C9 and VKORC1 genotypes
    • Valentin II, Vazquez J, Rivera-Miranda G. Prediction of warfarin dose reductions in Puerto Rican patients based on combinatorial CYP2C9 and VKORC1 genotypes. Ann. Pharmacother. 46(2), 208-218 (2012).
    • (2012) Ann. Pharmacother , vol.46 , Issue.2 , pp. 208-218
    • Valentin, I.I.1    Vazquez, J.2    Rivera-Miranda, G.3
  • 8
    • 77951498679 scopus 로고    scopus 로고
    • Integration of genetic, clinical and INR data to refine warfarin dosing
    • Lenzini PA, Wadelius M, Kimmel S et al. Integration of genetic, clinical and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5), 572-578 (2010).
    • (2010) Clin. Pharmacol. Ther , vol.87 , Issue.5 , pp. 572-578
    • Lenzini, P.A.1    Wadelius, M.2    Kimmel, S.3
  • 10
    • 45149100367 scopus 로고    scopus 로고
    • High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing
    • Ruaño G, Thompson PD, Villagra D et al High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing Pers. Med. 2008 5 225-232.
    • (2008) Pers. Med. , vol.5 , pp. 225-232
    • Ruaño, G.1    Thompson, P.D.2    Villagra, D.3
  • 11
    • 66849126349 scopus 로고    scopus 로고
    • Physiogenomic analysis of the Puerto Rican population
    • Ruaño G, Duconge J, Windemuth A et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics 10(4), 565-577 (2009).
    • (2009) Pharmacogenomics , vol.10 , Issue.4 , pp. 565-577
    • Ruaño, G.1    Duconge, J.2    Windemuth, A.3
  • 12
    • 84861146025 scopus 로고    scopus 로고
    • Application of the Fst statistics to explore pharmacogenomic diversity in the Brazilian population
    • Suarez-Kurtz G, Pena SDJ, Hutz MH. Application of the Fst statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics 13(7), 771-778 (2012).
    • (2012) Pharmacogenomics , vol.13 , Issue.7 , pp. 771-778
    • Suarez-Kurtz, G.1    Pena, S.D.J.2    Hutz, M.H.3
  • 13
    • 10744228888 scopus 로고    scopus 로고
    • Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
    • Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004).
    • (2004) Nature , vol.427 , Issue.6974 , pp. 537-541
    • Rost, S.1    Fregin, A.2    Ivaskevicius, V.3
  • 15
    • 21144448879 scopus 로고    scopus 로고
    • Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
    • Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005).
    • (2005) N. Engl. J. Med , vol.352 , Issue.22 , pp. 2285-2293
    • Rieder, M.J.1    Reiner, A.P.2    Gage, B.F.3
  • 16
    • 77954212927 scopus 로고    scopus 로고
    • CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies
    • Villagra D, Duconge J, Windemuth A. CYP2C9 and VKORC1 genotypes in Puerto Ricans: a case for admixture-matching in clinical pharmacogenetic studies. Clin. Chimica Acta 411, 1306-1311 (2010).
    • (2010) Clin. Chimica Acta , vol.411 , pp. 1306-1311
    • Villagra, D.1    Duconge, J.2    Windemuth, A.3
  • 17
    • 84857703472 scopus 로고    scopus 로고
    • Prediction of warfarin dose: Why when and how?
    • Eriksson N, Wadelius M. Prediction of warfarin dose: why, when and how? Pharmacogenomics 13(4), 429-440 (2012).
    • (2012) Pharmacogenomics , vol.13 , Issue.4 , pp. 429-440
    • Eriksson, N.1    Wadelius, M.2
  • 18
    • 77952495872 scopus 로고    scopus 로고
    • Implementing genotype-guided antithrombotic therapy
    • Seip RL, Duconge J, Ruaño G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 6, 409-424 (2010).
    • (2010) Future Cardiol , vol.6 , pp. 409-424
    • Seip, R.L.1    Duconge, J.2    Ruaño, G.3
  • 19
    • 58449087539 scopus 로고    scopus 로고
    • Pharmacogenomics of warfarin: Uncovering a piece of the warfarin mystery
    • Gulseth M, Grice G, Dager W. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am. J. Health Syst. Pharm. 66, 123-133 (2009).
    • (2009) Am. J. Health Syst. Pharm , vol.66 , pp. 123-133
    • Gulseth, M.1    Grice, G.2    Dager, W.3
  • 20
    • 33947227273 scopus 로고    scopus 로고
    • Association of warfarin dose with genes involved in its action and metabolism
    • Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
    • (2007) Hum. Genet , vol.121 , Issue.1 , pp. 23-34
    • Wadelius, M.1    Chen, L.Y.2    Eriksson, N.3
  • 21
    • 4143065736 scopus 로고    scopus 로고
    • Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype
    • Hillman MA, Wilke RA, Caldwell MD et al. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14, 539-547 (2004).
    • (2004) Pharmacogenetics , vol.14 , pp. 539-547
    • Hillman, M.A.1    Wilke, R.A.2    Caldwell, M.D.3
  • 22
    • 31344451857 scopus 로고    scopus 로고
    • Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
    • Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2), 101-110 (2006).
    • (2006) Pharmacogenet. Genomics , vol.16 , Issue.2 , pp. 101-110
    • Takahashi, H.1    Wilkinson, G.R.2    Nutescu, E.A.3
  • 23
    • 49949106034 scopus 로고    scopus 로고
    • Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans
    • Schelleman H, Chen J, Chen Z et al. Dosing algorithms to predict warfarin maintenance dose in Caucasians and African-Americans. Clin. Pharmacol. Ther. 84(3), 332-339 (2008).
    • (2008) Clin. Pharmacol. Ther , vol.84 , Issue.3 , pp. 332-339
    • Schelleman, H.1    Chen, J.2    Chen, Z.3
  • 25
    • 55449100859 scopus 로고    scopus 로고
    • VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans
    • Limdi NA, Beasley TM, Crowley MR et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10), 1445-1458 (2008).
    • (2008) Pharmacogenomics , vol.9 , Issue.10 , pp. 1445-1458
    • Limdi, N.A.1    Beasley, T.M.2    Crowley, M.R.3
  • 26
    • 24944503322 scopus 로고    scopus 로고
    • A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity
    • Yuan HY, Chen JJ, Lee MT et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum. Mol. Genet. 14(13), 1745-1751 (2005).
    • (2005) Hum. Mol. Genet , vol.14 , Issue.13 , pp. 1745-1751
    • Yuan, H.Y.1    Chen, J.J.2    Lee, M.T.3
  • 27
    • 34548060277 scopus 로고    scopus 로고
    • Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients
    • Nakai K, Tsuboi J, Okabayashi H et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 8(7), 713-719 (2007).
    • (2007) Pharmacogenomics , vol.8 , Issue.7 , pp. 713-719
    • Nakai, K.1    Tsuboi, J.2    Okabayashi, H.3
  • 28
    • 77949873283 scopus 로고    scopus 로고
    • Genetic and clinical predictors of warfarin dose requirements in African-Americans
    • Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African-Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
    • (2010) Clin. Pharmacol. Ther , vol.87 , Issue.4 , pp. 459-464
    • Cavallari, L.H.1    Langaee, T.Y.2    Momary, K.M.3
  • 29
    • 72849127064 scopus 로고    scopus 로고
    • Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
    • Pautas E, Moreau C, Gouin-Thibault I et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin. Pharmacol. Ther. 87(1), 57-64 (2010).
    • (2010) Clin. Pharmacol. Ther , vol.87 , Issue.1 , pp. 57-64
    • Pautas, E.1    Moreau, C.2    Gouin-Thibault, I.3
  • 30
    • 34347403221 scopus 로고    scopus 로고
    • Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes
    • Zhu Y, Shennan M, Reynolds KK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53(7), 1199-1205 (2007).
    • (2007) Clin. Chem , vol.53 , Issue.7 , pp. 1199-1205
    • Zhu, Y.1    Shennan, M.2    Reynolds, K.K.3
  • 31
    • 25144502325 scopus 로고    scopus 로고
    • Association of vitamin K epoxide reductase complex 1. (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
    • Veenstra DL, You JH, Rieder MJ et al. Association of vitamin K epoxide reductase complex 1. (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15(10), 687-691 (2005).
    • (2005) Pharmacogenet. Genomics , vol.15 , Issue.10 , pp. 687-691
    • Veenstra, D.L.1    You, J.H.2    Rieder, M.J.3
  • 32
    • 33645849823 scopus 로고    scopus 로고
    • Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements
    • Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
    • (2006) Clin. Pharmacol. Ther , vol.79 , pp. 291-302
    • Aquilante, C.L.1    Langaee, T.Y.2    Lopez, L.M.3
  • 33
    • 11244332058 scopus 로고    scopus 로고
    • A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin
    • D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005).
    • (2005) Blood , vol.105 , Issue.2 , pp. 645-649
    • D'Andrea, G.1    D'Ambrosio, R.L.2    Di Perna, P.3
  • 34
    • 4544288090 scopus 로고    scopus 로고
    • Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose
    • Zhao F. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin. Pharmacol. Ther. 76(3), 210-219 (2004).
    • (2004) Clin. Pharmacol. Ther , vol.76 , Issue.3 , pp. 210-219
    • Zhao, F.1
  • 35
    • 55449125520 scopus 로고    scopus 로고
    • Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics
    • Schelleman H, Limdi NA, Kimmel SE. Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics 9(9), 1331-1346 (2008).
    • (2008) Pharmacogenomics , vol.9 , Issue.9 , pp. 1331-1346
    • Schelleman, H.1    Limdi, N.A.2    Kimmel, S.E.3
  • 36
    • 34248159096 scopus 로고    scopus 로고
    • Warfarin dosing and the promise of pharmacogenomics
    • Dumas TE, Hawke RL, Lee CR. Warfarin dosing and the promise of pharmacogenomics. Curr. Clin. Pharmacol. 2, 11-21 (2007).
    • (2007) Curr. Clin. Pharmacol , vol.2 , pp. 11-21
    • Dumas, T.E.1    Hawke, R.L.2    Lee, C.R.3
  • 37
    • 23644437525 scopus 로고    scopus 로고
    • Common VKORC1 and GGCX polymorphisms associated with warfarin dose
    • Wadelius M, Chen LY, Downes K et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
    • (2005) Pharmacogenomics J , vol.5 , pp. 262-270
    • Wadelius, M.1    Chen, L.Y.2    Downes, K.3
  • 38
    • 67149091240 scopus 로고    scopus 로고
    • Validation of clinical testing for warfarin sensitivity: Comparison of CYP2C9-VKORC1 genotyping assays and warfarin dosing algorithms
    • Langley MR, Booker JK, Evans JP, McLeod HL, Keck KE. Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin dosing algorithms. J. Mol. Diagn. 11, 216-225 (2009).
    • (2009) J. Mol. Diagn , vol.11 , pp. 216-225
    • Langley, M.R.1    Booker, J.K.2    Evans, J.P.3    McLeod, H.L.4    Keck, K.E.5
  • 39
    • 84866738499 scopus 로고    scopus 로고
    • Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): Rationale and study design
    • Do EJ, Lenzini P, Eby CS et al. Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J. 12(5), 417-424 (2012).
    • (2012) Pharmacogenomics J , vol.12 , Issue.5 , pp. 417-424
    • Do, E.J.1    Lenzini, P.2    Eby, C.S.3
  • 40
    • 70649084116 scopus 로고    scopus 로고
    • Genotype-guided dosing of coumarin derivatives: The European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design
    • van Schie RM, Wadelius MI, Kamali F et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10(10), 1687-1695 (2009).
    • (2009) Pharmacogenomics , vol.10 , Issue.10 , pp. 1687-1695
    • Van Schie, R.M.1    Wadelius, M.I.2    Kamali, F.3
  • 41
    • 78349294600 scopus 로고    scopus 로고
    • Statistical design of personalized medicine interventions: The clarification of optimal anticoagulation through genetics (COAG) trial
    • French B, Joo J, Geller NL et al. Statistical design of personalized medicine interventions: the clarification of optimal anticoagulation through genetics (COAG) trial. Trials 11(1), 108. (2010).
    • (2010) Trials , vol.11 , Issue.1 , pp. 108
    • French, B.1    Joo, J.2    Geller, N.L.3
  • 42
    • 84863012482 scopus 로고    scopus 로고
    • Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy
    • Horne BD, Lenzini PA, Wadelius M et al. Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb. Haemost. 107, 232-240 (2012).
    • (2012) Thromb. Haemost , vol.107 , pp. 232-240
    • Horne, B.D.1    Lenzini, P.A.2    Wadelius, M.3
  • 43
    • 42349108153 scopus 로고    scopus 로고
    • Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients
    • Michaud V, Vanier MC, Brouillette D et al. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 83(5), 740-748 (2008).
    • (2008) Clin. Pharmacol. Ther , vol.83 , Issue.5 , pp. 740-748
    • Michaud, V.1    Vanier, M.C.2    Brouillette, D.3
  • 44
    • 80054989280 scopus 로고    scopus 로고
    • A proposal for an individualized pharmacogenetic-based warfarin initiation dose regimen for patients commencing anticoagulation therapy
    • Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohameh M, Kamali F. A proposal for an individualized pharmacogenetic-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin. Pharmacol. Ther. 90(5), 701-706 (2011).
    • (2011) Clin. Pharmacol. Ther , vol.90 , Issue.5 , pp. 701-706
    • Avery, P.J.1    Jorgensen, A.2    Hamberg, A.K.3    Wadelius, M.4    Pirmohameh, M.5    Kamali, F.6
  • 45
    • 20144363204 scopus 로고    scopus 로고
    • Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma
    • Choudhry S, Ung N, Avila PC et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am. J. Respir. Crit. Care Med. 171, 563-570 (2005).
    • (2005) Am. J. Respir. Crit. Care Med , vol.171 , pp. 563-570
    • Choudhry, S.1    Ung, N.2    Avila, P.C.3
  • 46
    • 44949094303 scopus 로고    scopus 로고
    • Pharmacogenetic response to albuterol among asthmatics
    • Corvol H, Gonzalez-Burchard E. Pharmacogenetic response to albuterol among asthmatics Pharmacogenomics 9(5), 505-510 (2008).
    • (2008) Pharmacogenomics , vol.9 , Issue.5 , pp. 505-510
    • Corvol, H.1    Gonzalez-Burchard, E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.